Su S, Huang X W
School of Clinical Medicine, Bethune Medical College, Jilin University, Changchun 130021, China.
Department of Liver Surgery and Transplantation, Zhongshan Hospital, Liver Cancer Institute, Fudan University, Shanghai 200032, China.
Zhonghua Gan Zang Bing Za Zhi. 2020 Jun 20;28(6):461-465. doi: 10.3760/cma.j.cn501113-20200420-00199.
Liver cancer is one of the most common malignant tumors and currently ranks the fourth in morbidity rate and the second in mortality rate in China. At present, the main clinical treatmentmethod is surgical treatment and other treatments, such as interventional therapy, local radiotherapy and chemotherapy, serve as supplementary treatment methods. However, due to the occult incidence of liver cancer, most patients have entered the advanced stage at the time of diagnosis and lack effective treatment methods, resulting in low overall survival rate, high mortality rate and poor prognosis. Immunotherapy, especially cellular immunotherapy, as an emerging cancer treatment method, can directly kill tumor cells or stimulate the anti-tumor immune response by isolating and activating immune effector cells. Common methods include chimeric antigen receptor T cells, tumor-infiltrating lymphocytes and cytokine-induced killer cells, etc. Recently, cellular immunotherapy has become a research hotspot because it can enhance the immune function, reduce the recurrence rate and prolong the survival time of patients. This article reviews the advances in the study of cellular immunotherapy in the clinical application of liver cancer.
肝癌是最常见的恶性肿瘤之一,目前在中国发病率排名第四,死亡率排名第二。目前,主要的临床治疗方法是手术治疗,其他治疗方法,如介入治疗、局部放疗和化疗,作为辅助治疗手段。然而,由于肝癌发病隐匿,大多数患者在确诊时已进入晚期,且缺乏有效的治疗方法,导致总体生存率低、死亡率高、预后差。免疫疗法,尤其是细胞免疫疗法,作为一种新兴的癌症治疗方法,可以通过分离和激活免疫效应细胞直接杀死肿瘤细胞或刺激抗肿瘤免疫反应。常见方法包括嵌合抗原受体T细胞、肿瘤浸润淋巴细胞和细胞因子诱导的杀伤细胞等。近年来,细胞免疫疗法因其能够增强免疫功能、降低复发率并延长患者生存时间而成为研究热点。本文综述了细胞免疫疗法在肝癌临床应用中的研究进展。